NCT02641938

Effect of Intraoperative Dexmedetomidine on Development of Acute Kidney Injury

Effect of Intraoperative Dexmedetomidine on Development of Acute Kidney Injury Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: a Double-blind Randomized Clinical Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: Gangnam Severance Hospital · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

To investigate the renal protective effect of dexmedetomidine in patients undergoing cytoreduction and hyperthermic intraperitoneal chemotherapy

Detailed description

A cytoreductive surgery and hyperthermic intraperitoneal chemotherapy may lead to the renal hypoperfusion, systemic inflammatory response, and oxidative stress. Dexmedetomidine has been known to protect the kidney against inflammation and oxidative stress in diverse clinical settings. It may also enhance a renal perfusion by inhibition of renal sympathoexcitation. We hypothesized administration of dexmedetomidine might protect the kidney in patients undergoing cytoreduction and hyperthermic intraperitoneal chemotherapy.

Conditions

• Malignant Tumor

Interventions

Type	Name	Description
DRUG	Dexmedetomidine	Dexmedetomidine group :1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia until the completion of the surgery
DRUG	Normal Saline	Control group :IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery

Timeline

• Start date: 2015-12-01
• Primary completion: 2017-11-01
• Completion: 2017-11-01
• First posted: 2015-12-30
• Last updated: 2018-01-02

Locations

1 site across 1 country: South Korea